UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE EXCHANGE ACT OF 1934 Commission File Number 001-36075 EVOKE PHARMA, INC. (Exact name of registrant as specified in its charter) Delaware 20-8447886 (State or other jurisdiction of incorporation) (IRS Employer Identificatio ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE EXCHANGE ACT OF 1934 Commission File Number 001-36075 EVOKE PHARMA, INC. (Exact name of registrant as specified in its charter) Delaware 20-8447886 (State or other jurisdiction of incorporation) (IRS Employer Identificati ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 Form 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2019 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to | --- | --- | --- | |----------------------------------------------------------------------------|---------------------------------------------------------------- ...

PART I. FINANCIAL INFORMATION [Item 1. Financial Statements](index=3&type=section&id=Item%201.%20Financial%20Statements) This section presents the unaudited condensed financial statements, including balance sheets, statements of operations, stockholders' equity, and cash flows, along with detailed notes explaining the company's organization, accounting policies, commitments, and key agreements, highlighting the company's financial position, operational performance, and cash movements for the reported periods [Condensed Balance Sheets](index=3&type=section&id=Condensed%20Balance%20Sheets) | Metric | Sep 30, 2019 (Unaudited) | Dec 31, 2018 | | :--------------------------- | :----------------------- | :----------- | | Cash and cash equivalents | $6,504,802 | $5,319,004 | | Total current assets | $7,291,960 | $5,648,222 | | Total assets | $7,327,358 | $5,659,773 | | Total current liabilities | $2,154,161 | $1,634,453 | | Total stockholders' equity | $5,173,197 | $4,025,320 | [Condensed Statements of Operations](index=4&type=section&id=Condensed%20Statements%20of%20Operations) | Metric | 3 Months Ended Sep 30, 2019 | 3 Months Ended Sep 30, 2018 | 9 Months Ended Sep 30, 2019 | 9 Months Ended Sep 30, 2018 | | :-------------------------------------------------- | :-------------------------- | :-------------------------- | :-------------------------- | :-------------------------- | | Research and development | $822,444 | $625,497 | $2,774,924 | $3,399,654 | | General and administrative | $814,218 | $897,060 | $2,955,371 | $2,846,611 | | Total operating expenses | $1,636,662 | $1,522,557 | $5,730,295 | $6,246,265 | | Net loss | $(1,628,065) | $(1,519,468) | $(5,707,427) | $(5,805,448) | | Net loss per share, basic and diluted | $(0.07) | $(0.09) | $(0.26) | $(0.36) | [Condensed Statements of Stockholders' Equity](index=5&type=section&id=Condensed%20Statements%20of%20Stockholders%27%20Equity) | Metric | Balance at Jan 1, 2019 | Balance at Sep 30, 2019 | Balance at Jan 1, 2018 | Balance at Sep 30, 2018 | | :--------------------------- | :--------------------- | :---------------------- | :--------------------- | :---------------------- | | Common Stock (Shares) | 17,427,533 | 24,231,914 | 15,413,610 | 17,427,533 | | Common Stock (Amount) | $1,743 | $2,423 | $1,541 | $1,743 | | Additional Paid-In Capital | $82,628,312 | $89,482,936 | $73,202,863 | $82,250,109 | | Accumulated Deficit | $(78,604,735) | $(84,312,162) | $(71,038,655) | $(76,844,103) | | Total Stockholders' Equity | $4,025,320 | $5,173,197 | $2,165,749 | $5,407,749 | [Condensed Statements of Cash Flows](index=6&type=section&id=Condensed%20Statements%20of%20Cash%20Flows) | Metric | 9 Months Ended Sep 30, 2019 | 9 Months Ended Sep 30, 2018 | | :------------------------------------------ | :-------------------------- | :-------------------------- | | Net cash used in operating activities | $(4,614,403) | $(5,729,646) | | Net cash provided by financing activities | $5,800,201 | $4,618,297 | | Net increase (decrease) in cash and cash equivalents | $1,185,798 | $(1,111,349) | | Cash and cash equivalents at end of period | $6,504,802 | $6,567,918 | [Notes to Condensed Financial Statements](index=7&type=section&id=Notes%20to%20Condensed%20Financial%20Statements) [1. Organization and Basis of Presentation](index=7&type=section&id=1.%20Organization%20and%20Basis%20of%20Presentation) - The Company is a specialty pharmaceutical company focused on developing **Gimoti™** for gastroenterological disorders, with its sole product candidate, **Gimoti**, receiving a **Complete Response Letter (CRL)** from the FDA on **April 1, 2019**, citing clinical pharmacology and product quality/device quality issues, but no new clinical data or safety concerns were raised[18](index=18&type=chunk) - The Company plans to resubmit the **Gimoti NDA** in **Q4 2019**, incorporating a root cause analysis for low drug exposure, patient use data, pump performance analysis, and 3-month stability data from commercial batches, with **no additional human clinical trials requested** by the FDA[18](index=18&type=chunk) - The Company has incurred recurring losses and negative cash flows, leading to **substantial doubt about its ability to continue as a going concern** for one year from the financial statements' issuance date, with existing cash projected to fund operations into **Q2 2020**, requiring additional funding from debt, equity, or collaboration arrangements[19](index=19&type=chunk) - The Company received a **Nasdaq delisting notice** on **May 15, 2019**, for failing to meet the minimum **$1.00 bid price** requirement, and while it does not expect to regain compliance by **November 11, 2019**, it intends to seek an additional **180-day compliance period**, potentially through a reverse stock split[22](index=22&type=chunk) [2. Summary of Significant Accounting Policies](index=8&type=section&id=2.%20Summary%20of%20Significant%20Accounting%20Policies) - The interim financial statements are prepared in accordance with **U.S. GAAP** and **SEC interim reporting requirements**, with certain footnotes condensed or omitted, and management's estimates and assumptions are crucial, with actual results potentially differing[23](index=23&type=chunk)[24](index=24&type=chunk) - The Company relies on third-party **CROs**, consultants, manufacturers (**Cosma S.p.A.** and **Thermo Fisher Scientific Inc.**), and sales/marketing organizations for **Gimoti's** development, manufacturing, and potential commercialization, where disruption in these relationships could materially affect the business[25](index=25&type=chunk)[29](index=29&type=chunk) - In **March 2018**, warrants were reclassified from liability to additional paid-in capital due to amendments, eliminating the need for fair value remeasurement at each reporting date[27](index=27&type=chunk) - Stock-based compensation expense is recorded at fair value and recognized over the service period, with estimates for exercise behavior, forfeiture rates, and volatility, while **R&D costs**, including pre-approval inventory, are expensed as incurred[28](index=28&type=chunk)[29](index=29&type=chunk) Potentially Dilutive Securities | Potentially Dilutive Securities | 3 Months Ended Sep 30, 2019 | 3 Months Ended Sep 30, 2018 | 9 Months Ended Sep 30, 2019 | 9 Months Ended Sep 30, 2018 | | :------------------------------ | :-------------------------- | :-------------------------- | :-------------------------- | :-------------------------- | | Warrants to purchase common stock | 2,713,561 | 2,713,561 | 2,713,561 | 2,713,561 | | Common stock options | 3,114,371 | 3,017,624 | 3,114,371 | 3,017,624 | | Employee stock purchase plan | 7,294 | 2,697 | 7,294 | 2,697 | | Total excluded securities | 5,835,226 | 5,733,882 | 5,835,226 | 5,758,937 | - The Company adopted **ASU No. 2016-02, Leases (Topic 842)**, effective **January 1, 2019**, recognizing a right-of-use (**ROU**) asset and lease liability for its operating lease[33](index=33&type=chunk) [3. Commitments](index=10&type=section&id=3.%20Commitments) - The Company has an operating lease for office space in Solana Beach, California, expiring **December 31, 2019**, and as of **January 1, 2019**, an operating lease **ROU asset and liability of approximately $136,000** were recorded[34](index=34&type=chunk) Rent Expense | Metric | 3 Months Ended Sep 30, 2019 | 3 Months Ended Sep 30, 2018 | 9 Months Ended Sep 30, 2019 | 9 Months Ended Sep 30, 2018 | | :----------- | :-------------------------- | :-------------------------- | :-------------------------- | :-------------------------- | | Rent expense | $36,000 | $35,000 | $109,000 | $104,000 | [4. Technology Acquisition Agreement](index=10&type=section&id=4.%20Technology%20Acquisition%20Agreement) - The Company acquired worldwide rights to **Gimoti** from Questcor (now Mallinckrodt) in **2007**, potentially owing up to **$52 million** in additional milestone payments, including a **$5 million** payment one year after FDA approval and **$47 million** contingent on commercial success[35](index=35&type=chunk) - A **low single-digit royalty** on net sales of **Gimoti** is also payable to Mallinckrodt until patent expiration in **2032**[35](index=35&type=chunk) [5. Stockholders' Equity](index=11&type=section&id=5.%20Stockholders%27%20Equity) - Through an at-the-market (**ATM**) offering program, the Company sold **6,804,381 shares** of common stock for approximately **$5.8 million net proceeds** during the nine months ended **September 30, 2019**, at a weighted-average price of **$0.87 per share**[37](index=37&type=chunk) - In **March 2018**, warrant amendments reclassified approximately **$3.3 million** from warrant liability to additional paid-in capital, resulting in a **net gain of approximately $433,000** in the statement of operations[39](index=39&type=chunk) - In **June 2019**, the Company completed a one-time option exchange, replacing **2,456,999 stock options** with **1,842,746 new options**, resulting in approximately **$84,000 of additional stock-based compensation expense** over four years[40](index=40&type=chunk) Stock-Based Compensation Expense | Stock-Based Compensation Expense | 3 Months Ended Sep 30, 2019 | 3 Months Ended Sep 30, 2018 | 9 Months Ended Sep 30, 2019 | 9 Months Ended Sep 30, 2018 | | :--------------------------------- | :-------------------------- | :-------------------------- | :-------------------------- | :-------------------------- | | Research and development | $179,227 | $161,515 | $533,518 | $519,025 | | General and administrative | $152,076 | $218,547 | $521,585 | $642,241 | | Total | $331,303 | $380,062 | $1,055,103 | $1,161,266 | [6. Commercial Services Agreement](index=12&type=section&id=6.%20Commercial%20Services%20Agreement) - On **January 5, 2019**, the Company entered into a commercial services agreement with **Novos Growth, LLC (NGP)** for **Gimoti's** commercialization, where **NGP** will manage a dedicated sales team[43](index=43&type=chunk) - The Company retains ownership of the **Gimoti NDA** and manufacturing responsibilities, recording sales and retaining **over 80% of product profits**, while **NGP** receives a **mid-to-high teens percentage of product profits** as a service fee[43](index=43&type=chunk) - Upon FDA approval, **NGP** will finance the Company's working capital needs for commercialization costs (**NGP Working Capital Loan**) and provide a line of credit up to **$5.0 million**, with repayment terms tied to positive Contribution Profits or specific termination events[43](index=43&type=chunk) - The **NGP Agreement** has a **five-year term** from commercial launch, with termination clauses for unmet sales thresholds, material breach, insolvency, safety recalls, or negative Contribution Profits, and while **NGP** could terminate if **Gimoti** wasn't approved by **April 30, 2019**, it has not done so as of **November 6, 2019**[45](index=45&type=chunk) [Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations](index=14&type=section&id=Item%202.%20Management%27s%20Discussion%20and%20Analysis%20of%20Financial%20Condition%20and%20Results%20of%20Operations) This section provides management's perspective on the company's financial condition, operational results, and future outlook, detailing the development status of Gimoti, regulatory challenges with the FDA, commercialization strategy, and the company's liquidity and capital resources, emphasizing going concern risk and Nasdaq listing compliance [Overview](index=14&type=section&id=Overview) - **Evoke Pharma** is a specialty pharmaceutical company developing **Gimoti**, a metoclopramide nasal spray for diabetic gastroparesis in women, with the FDA issuing a **Complete Response Letter (CRL)** for **Gimoti's NDA** on **April 1, 2019**, citing clinical pharmacology and product quality/device quality issues, but **no new clinical trials were requested**[49](index=49&type=chunk)[51](index=51&type=chunk) - The Company held a **Type A meeting** with the FDA on **July 25, 2019**, and plans to resubmit the **NDA** in **Q4 2019**, addressing **CRL** deficiencies with a root cause analysis, patient use data, pump performance analysis, and 3-month stability data[51](index=51&type=chunk) - A commercial services agreement with **NGP** was signed on **January 5, 2019**, for **Gimoti's** commercialization, with **NGP** managing a dedicated sales team and providing working capital financing and a line of credit upon FDA approval[51](index=51&type=chunk) - The Company has incurred significant losses since inception, has no approved products or revenue, and expects continued losses, with cash and cash equivalents of approximately **$6.5 million** as of **September 30, 2019**, expected to fund operations into **Q2 2020**, but **additional funding is required to continue as a going concern**[51](index=51&type=chunk)[53](index=53&type=chunk) [Technology Acquisition Agreement](index=16&type=section&id=Technology%20Acquisition%20Agreement) - The Company acquired **Gimoti** rights from Questcor (now Mallinckrodt) in **2007**, with future milestone payments potentially totaling up to **$52 million**, including a **$5 million** payment one year post-FDA approval and **$47 million** contingent on commercial success[54](index=54&type=chunk) - A **low single-digit royalty** on net sales of **Gimoti** is also payable to Mallinckrodt until patent expiration in **2032**[54](index=54&type=chunk) [Financial Operations Overview](index=16&type=section&id=Financial%20Operations%20Overview) - **Research and development expenses** are expensed as incurred and primarily include clinical trial costs, **CRO** and consultant fees, manufacturing and stability testing, and employee-related expenses, with all **R&D expenses** to date dedicated to **Gimoti**[55](index=55&type=chunk) - **General and administrative expenses** consist mainly of salaries, benefits, stock-based compensation, professional fees (accounting, legal, patent), insurance, and public company costs, and these expenses are expected to increase with expanded operations and potential commercialization[59](index=59&type=chunk) - **Other income** primarily reflects changes in the fair value of warrant liability, which ceased to be revalued after warrant amendments in **March 2018** reclassified them to additional paid-in capital[60](index=60&type=chunk) - Critical accounting policies and significant judgments and estimates are consistent with those disclosed in the **Annual Report on Form 10-K** for the fiscal year ended **December 31, 2018**[61](index=61&type=chunk) [Results of Operations](index=17&type=section&id=Results%20of%20Operations) [Comparison of Three Months Ended September 30, 2019 and 2018](index=17&type=section&id=Comparison%20of%20Three%20Months%20Ended%20September%2030,%202019%20and%202018) Expense Category Comparison (3 Months) | Expense Category | 3 Months Ended Sep 30, 2019 | 3 Months Ended Sep 30, 2018 | Increase/(Decrease) | | :----------------------- | :-------------------------- | :-------------------------- | :------------------ | | Research and development | $822,444 | $625,497 | $196,947 | | General and administrative | $814,218 | $897,060 | $(82,842) | - **R&D expenses increased by approximately $197,000**, primarily due to costs for responding to FDA requests and manufacturing registration batches of **Gimoti** in **2019**, compared to **NDA-related responses in 2018**[64](index=64&type=chunk) - **G&A expenses decreased by approximately $83,000**, mainly due to lower wages, taxes, employee insurance, and stock-based compensation in **2019** compared to **2018**[65](index=65&type=chunk) [Comparison of Nine Months Ended September 30, 2019 and 2018](index=18&type=section&id=Comparison%20of%20Nine%20Months%20Ended%20September%2030,%202019%20and%202018) Expense Category Comparison (9 Months) | Expense Category | 9 Months Ended Sep 30, 2019 | 9 Months Ended Sep 30, 2018 | Increase/(Decrease) | | :----------------------- | :-------------------------- | :-------------------------- | :------------------ | | Research and development | $2,774,924 | $3,399,654 | $(624,730) | | General and administrative | $2,955,371 | $2,846,611 | $108,760 | | Other (income) | $(22,868) | $(440,817) | $(417,949) | - **R&D expenses decreased by approximately $625,000**, primarily due to lower **NDA preparation costs in 2019** compared to **2018**, despite ongoing FDA responses and manufacturing[66](index=66&type=chunk) - **G&A expenses increased by approximately $109,000**, driven by higher legal, accounting, and public company costs, as well as outside consultants and pre-commercialization costs in **2019**[67](index=67&type=chunk) - **Other income decreased by approximately $418,000**, mainly because warrants were no longer revalued as a liability after their reclassification to equity in **March 2018**[67](index=67&type=chunk) [Liquidity and Capital Resources](index=18&type=section&id=Liquidity%20and%20Capital%20Resources) - The Company raised approximately **$5.8 million** in net proceeds from selling **6,804,381 common shares** through its **ATM offering** during the nine months ended **September 30, 2019**, with **$5.4 million** remaining available under the **Form S-3 shelf registration** as of **September 30, 2019**[69](index=69&type=chunk) - Due to a public float of approximately **$21.0 million** as of **October 31, 2019**, the Company is subject to '**baby shelf rules**,' limiting primary public offerings to **one-third of its public float** (approximately **$1.1 million capacity remaining** under **FBR Sales Agreement**)[69](index=69&type=chunk) - Management concluded there is **substantial doubt about the Company's ability to continue as a going concern**, with existing cash expected to fund operations only into **Q2 2020**, and additional financing is required, as failure to secure it could lead to liquidation[69](index=69&type=chunk)[94](index=94&type=chunk) - The Company received a **Nasdaq delisting notice** on **May 15, 2019**, for failing to meet the minimum **$1.00 bid price**, and while it does not expect to regain compliance by **November 11, 2019**, it intends to seek an additional **180-day compliance period**, potentially through a reverse stock split[69](index=69&type=chunk)[71](index=71&type=chunk) Cash Flow Activity Comparison | Cash Flow Activity | 9 Months Ended Sep 30, 2019 | 9 Months Ended Sep 30, 2018 | Increase/(Decrease) | | :------------------------------------------ | :-------------------------- | :-------------------------- | :------------------ | | Net cash used in operating activities | $(4,614,403) | $(5,729,646) | $(1,115,243) | | Net cash provided by financing activities | $5,800,201 | $4,618,297 | $1,181,904 | | Net increase (decrease) in cash and cash equivalents | $1,185,798 | $(1,111,349) | $2,297,147 | - Operating cash use decreased due to lower **R&D expenses**, while financing cash increased due to higher proceeds from common stock sales[72](index=72&type=chunk)[73](index=73&type=chunk) [Off-Balance Sheet Arrangements](index=21&type=section&id=Off-Balance%20Sheet%20Arrangements) - As of **September 30, 2019**, the Company had **no material off-balance sheet arrangements**[76](index=76&type=chunk) [Contractual Obligations and Commitments](index=21&type=section&id=Contractual%20Obligations%20and%20Commitments) - There were **no material changes** to contractual obligations outside the ordinary course of business during the nine months ended **September 30, 2019**, compared to the prior **Annual Report on Form 10-K**[77](index=77&type=chunk) [Item 3. Quantitative and Qualitative Disclosures about Market Risk](index=21&type=section&id=Item%203.%20Quantitative%20and%20Qualitative%20Disclosures%20about%20Market%20Risk) This section states that there have been no material changes in the company's market risk since the last annual report - **No material changes** in market risk were reported as of **September 30, 2019**, compared to the **Annual Report on Form 10-K** for the fiscal year ended **December 31, 2018**[78](index=78&type=chunk) [Item 4. Controls and Procedures](index=21&type=section&id=Item%204.%20Controls%20and%20Procedures) This section confirms the effectiveness of the company's disclosure controls and procedures and reports no material changes in internal control over financial reporting - Management, including the **CEO** and **CBO**, concluded that the Company's **disclosure controls and procedures were effective** at a reasonable assurance level as of **September 30, 2019**[79](index=79&type=chunk) - There have been **no material changes** in the Company's internal control over financial reporting during the most recent fiscal quarter[80](index=80&type=chunk) PART II. OTHER INFORMATION [Item 1. Legal Proceedings](index=22&type=section&id=Item%201.%20Legal%20Proceedings) This section states that the company is not involved in any material legal proceedings - The Company is **not currently a party to any material legal proceedings**[82](index=82&type=chunk) [Item 1A. Risk Factors](index=22&type=section&id=Item%201A.%20Risk%20Factors) This section updates the risk factors, primarily focusing on the critical dependence on Gimoti's regulatory approval, the substantial need for additional funding, the ongoing going concern uncertainty, and the risk of delisting from Nasdaq - The Company's business is entirely dependent on the success of **Gimoti**, which received a **Complete Response Letter (CRL)** from the FDA, creating **uncertainty about regulatory approval and commercialization**[83](index=83&type=chunk)[85](index=85&type=chunk) - The FDA's **CRL** cited clinical pharmacology and product quality/device quality issues, requiring a root cause analysis and additional data for resubmission, with **no assurance that the FDA will approve the NDA or not require further clinical trials**[83](index=83&type=chunk)[85](index=85&type=chunk)[89](index=89&type=chunk) - The Company requires **substantial additional funding** beyond its current cash, which is projected to last only into **Q2 2020**, and failure to raise capital would force the Company to curtail operations or liquidate, leading to a **complete loss of investment**[86](index=86&type=chunk)[88](index=88&type=chunk)[94](index=94&type=chunk) - The Company faces a **risk of delisting from The Nasdaq Capital Market** due to its common stock trading below the **minimum $1.00 bid price requirement**, and while it plans to seek an additional compliance period, there's **no assurance of regaining compliance**[99](index=99&type=chunk) - Commercialization of **Gimoti**, if approved, relies on **NGP** and other third parties for sales and marketing, and any failure in these partnerships or inability to build internal capabilities could **severely limit revenue generation**[91](index=91&type=chunk)[93](index=93&type=chunk) [Item 2. Unregistered Sales of Equity Securities and Use of Proceeds](index=28&type=section&id=Item%202.%20Unregistered%20Sales%20of%20Equity%20Securities%20and%20Use%20of%20Proceeds) This section confirms that there were no unregistered sales of equity securities during the reporting period - There were **no unregistered sales of equity securities**[101](index=101&type=chunk) [Item 3. Defaults Upon Senior Securities](index=28&type=section&id=Item%203.%20Defaults%20Upon%20Senior%20Securities) This section states that there were no defaults upon senior securities - There were **no defaults upon senior securities**[102](index=102&type=chunk) [Item 4. Mine Safety Disclosure](index=28&type=section&id=Item%204.%20Mine%20Safety%20Disclosure) This section indicates that mine safety disclosure is not applicable to the company - **Mine Safety Disclosure is not applicable**[102](index=102&type=chunk) [Item 5. Other Information](index=28&type=section&id=Item%205.%20Other%20Information) This section states that there is no other information to report - **No other information to report**[102](index=102&type=chunk) [Item 6. Exhibits](index=29&type=section&id=Item%206.%20Exhibits) This section provides a comprehensive list of all exhibits filed as part of the Form 10-Q, including corporate documents, warrant forms, certifications, and XBRL taxonomy documents - The report includes various exhibits such as **Amended and Restated Certificate of Incorporation**, **Bylaws**, **Common Stock Certificate Form**, **Investor Rights Agreement**, **Warrant forms and amendments**, and certifications (**CEO, CFO**) under the **Securities Exchange Act** and **Sarbanes-Oxley Act**[104](index=104&type=chunk) - **XBRL Instance, Schema, Calculation, Definition, and Label Linkbase Documents** are also furnished as exhibits[104](index=104&type=chunk) [SIGNATURES](index=30&type=section&id=SIGNATURES) This section contains the official signatures of the company's authorized officers, certifying the submission of the report - The report is duly signed on behalf of **Evoke Pharma, Inc.** by **David A. Gonyer, President and Chief Executive Officer**, and **Matthew J. D'Onofrio, Executive Vice President, Chief Business Officer, Treasurer and Secretary**, on **November 7, 2019**[106](index=106&type=chunk)[108](index=108&type=chunk)[109](index=109&type=chunk)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2019 OR ☐ TRANSITION REPORT UNDER SECTION 13 OF 15(d) OR THE EXCHANGE ACT OF 1934 Commission File Number 001-36075 EVOKE PHARMA, INC. (Exact name of registrant as specified in its charter) Delaware 20-8447886 (State or other jurisdiction of incorporation) (IRS Employer Identification No. ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 Form 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2018 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to | --- | --- | --- | |---------------------------------------------------------------------------------------|----------------------------------------------------- ...